2014.Dec.08

未分類

Corporate

Cancer Active Immunotherapy OBI-822 Mechanism Action

HOMEWhat’s NewNewsCancer Active Immunotherapy OBI-822 Mechanism Action

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2014.Dec.08

Introduction of OBI PHARMA, INC.’s

2015.Jun.04

Clarification about the Progressive Disease (PD) number of the OPT-822-001 Clinical Trial as reported in the Taiwan Media on 4 June 2015